Sue Kiddie Medical Herbalist

21/07/2026

A new 12-week randomised, double blind, placebo-controlled trial has provided the strongest clinical evidence to date supporting saffron as a treatment for low mood and depressive symptoms (subclinical depression). Enrolling 202 adults aged 18 to 70 years, it is the largest clinical trial ever conducted on saffron for mood disorders and probably the most methodologically rigorous saffron study published to date.

The study used a proprietary saffron extract at a dose of 28 mg/day. Subclinical, subthreshold, or minor depression is defined as the presence of depressive symptoms but without fulfilling all the diagnostic criteria for major depressive disorder (MDD). Although participants in the trial did not have formally diagnosed MDD, their baseline DASS-21 (Depression, Anxiety and Stress Scale-21) scores averaged around 22, placing many in the severe symptom range despite being classified as ‘subclinical.’ At the same time, the cohort was relatively medically uncomplicated, with exclusions for major psychiatric diagnoses, significant medical illness, heavy alcohol use, smoking, ongoing psychotherapy and several medication classes, thereby creating a low-mood population largely free of potential confounders.

The primary outcome showed a statistically significant antidepressant effect favouring saffron. DASS-21 scores fell by 11.34 points in the saffron group compared with 8.42 points in the placebo group, producing a modest but clinically meaningful between-group effect size (Cohen’s d = 0.39, P = 0.010). Particularly noteworthy was the responder analysis: 72.3% of saffron-treated participants achieved a clinically meaningful reduction of at least 7 points on the DASS-21 depression scale compared with 54.3% in the placebo group (P = 0.010). However, the study also highlighted the enormous placebo responses that can be seen in low-mood trials. Much of the improvement occurred in both groups during the first 4 weeks, suggesting strong expectancy and nonspecific trial-participation effects.

Importantly though, the placebo response largely plateaued thereafter, whereas the saffron group continued gradual improvement across the full 12 weeks. This temporal divergence arguably strengthens the credibility of the findings because it suggests saffron may exert a progressively accumulating physiological effect rather than simply producing a short-lived expectancy response. Even longer treatment durations may have resulted in a larger separation between saffron and placebo.

Saffron did not significantly outperform placebo on most secondary measures including anxiety, stress and general wellbeing, although favourable trends were observed. The sleep findings were particularly interesting. Overall sleep outcomes were not statistically significant across the entire cohort, but exploratory subgroup analyses revealed meaningful improvements in participants with more substantial baseline sleep disturbance. In these participants, effect sizes for sleep improvement approached or slightly exceeded those seen for depression itself (d = 0.44). This suggests saffron’s sleep effects may be conditional and phenotype-dependent rather than universally sedative. The study also strengthened its methodological credibility by applying several observances: adjusting analyses for treatment expectancy effects, using intention-to-treat and per-protocol analyses, and incorporating daily mood ratings across the study duration.

The safety profile was excellent, with over 95% of participants rating tolerability as good or excellent and only a handful of mild treatment-related adverse events reported, including headache, abdominal pain and itchy skin. Overall, this landmark study substantially strengthens the evidence base supporting saffron as a genuine antidepressant phytomedicine, while simultaneously illustrating the profound challenge of the placebo response in mood research. But to my thinking, the very magnitude of the placebo response may actually enhance the credibility of the trial itself, because it reflects the real world.

In summary, this is arguably the most methodologically credible saffron mood trial yet conducted because of its size, duration, expectancy adjustment and rigorous analyses. The findings support saffron as a modest but clinically meaningful intervention for depressive symptoms, particularly in relatively healthy individuals, while also suggesting that its effects may accumulate progressively over time and potentially extend to sleep benefits in symptom-specific subgroups.

For more information see: https://pubmed.ncbi.nlm.nih.gov/40414301/

26/05/2026

Lovely summary of Mullein! 🌿

🌿 Deep Dive: Mullein — The Soft, Fuzzy Herb with Powerful Healing Potential ✨

If you have ever spotted a tall stalk of soft, silvery-green leaves growing along a field edge or roadside and wondered what it was, chances are you were looking at Mullein (Verbascum thapsus). This humble plant may look like a common w**d at first glance, but herbalists have treasured it for generations as a gentle yet powerful ally for the lungs, the ears, and the skin.

In our newest infographic, The Bioactive Blueprint of Mullein, we take a closer look at the traditional uses and fascinating plant chemistry that make this herb such a staple in the home apothecary.

🫁 A Classic Herb for the Lungs
Mullein is best known for its long-standing reputation as a respiratory herb. It has been traditionally used to soothe dry, irritated airways and support the body during coughs, bronchial irritation, and seasonal respiratory discomfort. This is one of those herbs many herbalists immediately think of when the lungs need something gentle, moistening, and calming.

👂 A Traditional Favorite for Ear Support
Mullein flower oil is another time-honored preparation that herbalists have turned to for generations. Infusing the flowers in olive oil creates one of the best-known traditional remedies for soothing ear discomfort and supporting irritated ears naturally.

🩹 Gentle Support for Skin and Tissue
Mullein is not just a lung herb. The leaves and flowers have also been used topically to support the healing of minor wounds, burns, dry irritated skin, and other inflammatory skin issues. It is one of those plants that seems to bring a softening, soothing quality wherever it is applied.

🦠 More Than Just Soothing
Beyond its reputation as a comforting herb, Mullein is also valued for its broad protective properties. Traditional herbal practice has long recognized it as a plant that helps the body respond to microbial imbalance while also calming irritation and inflammation at the same time.

🧪 The Chemistry Behind the Magic
What makes Mullein so special? A big part of the answer lies in its chemistry. This beautiful plant contains mucilage for soothing, saponins for supporting healthy respiratory clearing, and a rich mix of flavonoids and iridoids that contribute to its calming and protective actions. It is a wonderful example of how a plant’s texture, tradition, and chemistry all line up in a way that makes perfect herbal sense.

🌱 A W**d Worth Knowing
Here at Grow, Gather, Heal, we love plants like Mullein because they remind us that some of the most valuable herbs are often growing right in plain sight. Soft, resilient, and deeply useful, Mullein absolutely earns its place in the herbal toolkit.

Have you ever used Mullein tea or flower oil in your home apothecary? Tell us in the comments! 👇

02/03/2026

Spring clean!!🌿

🌿MARCH - THE MONTH OF GENTLE MEDICINE🌿

After winter, our bodies often feel heavier, slower, and more stagnant, and that’s completely natural. Cold weather, richer foods, less movement, and less sunlight all encourage us to conserve energy. We rest more, digest more slowly, and tend to hold onto fluids and waste.

Spring plants grow in direct response to those exact conditions.

The first greens that pop up in March are light, bitter, mineral-rich, and gently stimulating. It’s nature’s way of helping us transition out of winter mode. These plants support the organs of elimination, get circulation moving again, and wake up digestion that’s been moving at a slower pace.

A few often-overlooked UK spring medicinal herbs we love working with:

🌿Chickw**d - cooling & soothing
🌿Sorrel - lemony digestive support
🌿Ground Ivy - traditional respiratory ally
🌿Meadowsweet - calming digestive support

Taking time to learn even one or two local plants can deepen your understanding of seasonal cycles and help you reconnect with the natural rhythms happening right outside your door. Building a relationship with plants slowly, observing how they grow, when they emerge, and how they support the body, creates a strong foundation for herbal learning.

👉 Read more on the blog at www.betonica.co.uk/herbal-news

⚠️ Always positively identify any plant before use. If you’re pregnant, taking medications, or managing health conditions, consult a qualified medical herbalist or healthcare provider before taking herbs.

17/02/2026

One of the core components of my microcirculation phytonutrient diet is cocoa, usually as very dark chocolate (85 to 90%), chosen for its higher flavanol density and lower sugar load. A 2025 systematic review rigorously evaluated the clinical evidence to determine whether cocoa flavanols meaningfully enhance microvascular function. The review included 19 randomised, placebo-controlled human trials, comprising 13 acute studies and 7 chronic studies (with one study containing both phases), spanning effects on skin, skeletal muscle, cerebral and retinal microvascular beds.

Participants were not simply eating ordinary chocolate. Most of the trials used standardised, high-flavanol cocoa beverages, concentrated cocoa extracts in capsules, or specially prepared high-percentage dark chocolate, delivering pharmacological doses of flavanols. Acute doses commonly ranged from 500 to 1350 mg total flavanols (with 45 to 255 mg of (-)-epicatechin), and some chronic studies delivered up to 900 to 1800 mg/day.

A conventional meta-analysis was not possible because the studies varied widely in assessed vascular beds, measurement techniques (Laser Doppler, plethysmography etc), and stimulus conditions (reactive hyperaemia, hypoxia, mental stress, exercise). The authors therefore used vote counting, a Cochrane-recognised fallback method. In this approach, each study subgroup was assigned a “vote” based solely on whether cocoa performed better than placebo (1) or not (0), regardless of statistical significance or effect size. They then tested whether the proportion of positive directions exceeded chance (50%).

Using vote counting (direction-of-effect analysis), 12 of 14 acute subgroups (85.7%) showed improved vasodilator responses with cocoa flavanols, a proportion significantly greater than chance (p = 0.013), with 100% of the low-risk-of-bias (higher quality) acute studies favouring cocoa. For chronic supplementation, the direction was also generally favourable but less robust: 8 of 11 subgroups (72.7%) showed improved vasodilator responses and 7 of 9 (77.7%) favoured cocoa at rest, but these proportions did not reach statistical significance. (Note that some trials generated more than one subgroup for analysis.)

Hence the strongest signal was for acute enhancement of microvascular reactivity within 1 to 3 hours after ingestion, coinciding with peak circulating flavanol metabolites and nitric oxide-related activity. Chronic effects were less consistent, and there was little evidence of structural microvascular remodelling or reversal of established disease. The current clinical data therefore position high-dose cocoa flavanol extracts as performance enhancing short-term endothelial modulators that may enhance vascular responsiveness under stress (cognitive demand, hypoxia, reactive hyperaemia).

The fact that the clinical evidence favours acute effects from cocoa does not rule out benefits from long-term chronic intake. However, it does highlight that the use of a multicomponent sustained input, as per my microcirculation diet, is more likely to have the greatest impact on chronic microvascular compromise.

For more information see: https://pubmed.ncbi.nlm.nih.gov/40217225/

26/01/2026

Even with unprecedented investment, the dementia drug pipeline continues to deliver modest and uncertain gains at best. Despite the media fanfare, recent agents largely target late-stage amyloid pathology, offering small statistical benefits that translate into limited real-world clinical impact, while carrying substantial costs and safety concerns. There is little in the current pipeline that convincingly alters disease trajectory once neurodegeneration is established. This sobering reality underlines a critical truth: dementia is unlikely to be “cured” pharmacologically after onset. The greatest opportunity lies earlier—shifting focus toward prevention and delay through vascular health, metabolic resilience, inflammation control, and lifelong neuroprotection—where the biological leverage, population impact, and cost-effectiveness are far greater.

A recent umbrella review underlines that we already know a good deal about what to do. A total of 45 reviews covering 212 meta-analyses (including around 10,000 individual studies in total) were synthesised. From this the authors identified 14 broadly defined modifiable risk factors that were significantly associated with dementia disorders.

They were: alcohol consumption, body weight, depression, diabetes mellitus, diet, hypertension, less education, physical inactivity, sensory loss, sleep disturbance, smoking, social isolation, traumatic brain injury and vitamin D deficiency. All 14 factors were associated with the risk of major neurocognitive disorders (NCD), and five were associated with mild NCD. Of note, the scientists found considerably less research for vascular dementia and mild NCD.

The study highlighted the role of a key nutrient in prevention, namely vitamin D. Beyond vitamin D, several B vitamins and selected herbs may contribute meaningfully to dementia prevention. Folate and vitamin B12 are central to homocysteine metabolism; elevated homocysteine is strongly linked to brain atrophy, white-matter damage and faster cognitive decline, with trials suggesting benefit when deficiencies or low-normal levels are corrected. Among herbs, Ginkgo biloba has the most consistent human evidence, supporting cerebral microcirculation and endothelial function and mitochondrial activity. Turmeric (particularly bioavailable curcumin) targets neuroinflammation, oxidative stress and amyloid pathology. Low-dose lithium, even at trace nutritional levels, has emerging epidemiological and clinical support for neuroprotection, possibly reduced tau phosphorylation and enhanced neuronal resilience.

For more information see: https://pubmed.ncbi.nlm.nih.gov/38346414/

15/12/2025

HERBS AND SPICES GETTING US THROUGH DECEMBER

As the festive season rolls in, many of us find ourselves reaching for those cosy herbs and spices that make winter cooking feel warm and comforting. Beyond tasting great, they have a long history of supporting circulation, immunity, and general wellbeing—especially handy when the cold weather and winter bugs kick in.

We’ve gathered some of our favourite winter herbs and spices, along with a few simple recipes, to help add a little more warmth and nourishment to your December.

👉 Find them all in our latest blog post. Link in profile.